ENGLISH

TRAIL, Fas Ligand, TNF and TLR3 in Cancer

By Olivier Micheau (eds.)

Book information

Publisher
Springer International Publishing
Year
2017
ISBN
978-3-319-56804-1, 978-3-319-56805-8
Language
english
Format
PDF
Filesize
8 MB (8634459 bytes)
Series
Resistance to Targeted Anti-Cancer Therapeutics 12
Pages
\320
Time added
2017-08-08 21:00:00
Cancer Research

Description

Front Matter....Pages i-xiii Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer....Pages 1-25 TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer....Pages 27-57 IAPs and Resistance to Death Receptors in Cancer....Pages 59-77 Bcl-2 Proteins and TRAIL Resistance in Melanoma....Pages 79-90 Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4....Pages 91-106 Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy....Pages 107-129 Atypical Immune Functions of CD95/CD95L....Pages 131-157 TLR3 Is a Death Receptor Target in Cancer Therapy....Pages 159-185 Fas/CD95, Lipid Rafts, and Cancer....Pages 187-227 Role of Sphingolipids in Death Receptor Signalling....Pages 229-245 Posttranslational Modifications and Death Receptor Signalling....Pages 247-290 System Modeling of Receptor-Induced Apoptosis....Pages 291-307 Back Matter....Pages 309-317

Similar books